Navigation Links
OncoGenex Pharmaceuticals' Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
Date:5/11/2009

eaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning the Company's key objectives for 2009, and other anticipated activities, achievements, occurrences and performance. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements.

The potential risks and uncertainties associated with forward-looking statements include, among others, the timing and costs of clinical trials and regulatory approvals, risks that clinical trials will not be successful or confirm earlier or interim clinical trial results, the Company's need for additional financing, the uncertainty associated with any potential partnering discussions, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal year 2008 and its Quarterly Report for the first quarter of 2009 on Form 10-Q. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or that if any of them do transpire or occur, what impact they would have on the results of operations or financial condition of the Company. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. OncoGenex Reports First Quarter Financial Results
2. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
3. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
4. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
5. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
6. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
7. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
8. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
9. OncoGenex Reports Third Quarter Financial Results
10. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
11. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Raleigh, NC (PRWEB) May 21, 2013 ... and financial services company for clinical trials, announced ... Aggregate Spend Solutions, LLC. Clinverse’s ClinPay® FLS ... automated investigator payment process. SpendMD ™, ... only complete solution for tracking and reporting transfer ...
(Date:5/21/2013)... As the R&D sector becomes increasingly ... industry to deliver better products, faster. Collaborations between ... often means turning big ideas into reality, within ... with Sensidose AB and Recipharm, is one example ... market sooner. The partnership resulted in the development ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. ... study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal ... expressing the HER2 oncoprotein," will be presented at ... of Clinical Oncology during the Developmental Therapeutics - ... at 4:15 – 4:30 PM.  The presentation will ...
(Date:5/21/2013)... 2013 Bed bugs have become so widespread ... Products, many turn to chemical-based pesticides for help to completely ... environmental risks those solutions present, the company advised the public ... instead. , According to My Cleaning Products, chemical-based pesticides ... to be. It shared that the pests have already developed ...
Breaking Biology Technology:Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3
... The University of Wisconsin-Madison Department of Educational Psychology has ... Distributed Learning Co-Lab to create new worlds in ... , ,"The Department's Learning Sciences Program studies ... , professor in UW-Madison's School of Education. "We have ...
... , a supplier of premium tools for proteomics and ... strategic partnership with The Automation Partnership (TAP), ... applications. , ,This partnership is designed to enable ... on the Piccolo system, TAP's fully automated system for ...
... the greatest obstacles in taking care of a patient ... Patient histories and care instructions are often long and ... involved, more levels of complication develop. To many, a ... like a Holy Grail, a treasure for doctors and ...
Cached Biology Technology:University of Wisconsin team creates learning games 2University of Wisconsin team creates learning games 3EMD Biosciences partners with European biotech company 2Human factors and IT: Designing for patient safety 2Human factors and IT: Designing for patient safety 3
(Date:5/21/2013)... ANN ARBORThe new University of Michigan Water Center ... to support Great Lakes restoration and protection efforts. ... will support diverse projects, including efforts to track ... effectiveness of techniques to control non-native weedy plant ... and monitor fish responses to restoration activities. , ...
(Date:5/21/2013)... world,s largest scientific society, invites news media coverage ... 8-12, 2013, in Indianapolis, Ind. It will take ... area hotels. , With more than 7,100 presentations ... from astronomy to zoology ― the meeting will ... assortment of spot news and feature possibilities. The ...
(Date:5/21/2013)... May 21, 2013 Royal Philips Electronics (NYSE: ... world,s first portable ultrasound with Philips, industry leading Live ... The CX50 xMATRIX with available Live 3D TEE and ... at the EuroPCR, official meeting for the European ... Since its launch in 2012, Philips CX50 xMATRIX ...
Breaking Biology News(10 mins):U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2
... forests in lowland areas of Mediterranean mountains could expand by up ... that are more adapted to cold and humid conditions, such as ... scenarios could be quite possible in the 21st century according to ... the forests of the Sistema Central and the Sistema Ibrico (Spain). ...
... and research institutions, and other stakeholders have joined together ... for food and agriculture. This initiative represents one of ... in support of science for food and agriculture. ... Joint Select Committee on Deficit Reduction (the "super committee") ...
... among the most threatened creatures on earth, with some 40 ... primary threats is a rapidly spreading disease that attacks the ... been a key factor in the extinctions of many species ... of biological sciences in the College of Science at Virginia ...
Cached Biology News:Holm oaks will gain ground in northern forests due to climate change 21,200 speak up for Federal research funding for Food and Agriculture 2Research team explores how microbial diversity defends against disease 2Research team explores how microbial diversity defends against disease 3
... Science Major Science MS 300V (Cat. No. ... designed to meet most electrophoresis needs in ... Major Science MS 300V power supply ... instruments used in electrophoresis. 4 pairs of ...
...
The Programmable MP-3500P-F Power Supply can be applied for any Microfluidic application....
Rabbit polyclonal to Synapsin II ( Abpromise for all tested applications). entrezGeneID: 6854 SwissProtID: Q92777...
Biology Products: